Stay updated with breaking news from Rachel Eides. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 - EMA and MHRA submissions are on track for Q4 2022 - Exa-cel
Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be
- Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR
ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today... | May 12, 2022
ZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company...